ERBB2 and cancer: Resistance mechanisms against CTLs, as well as increased expression of survival proteins [e.g., B-cell lymphoma 2 protein (BCL-2)] and tyrosine kinase receptors overexpression [e.g., human epidermal growth factor receptor 2 (HER2/neu)] can be developed by cancer cells (Figure 2).